Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 684-693

  Mcilhatton, Michael A ^a   Tyler, Jessica ^a   Kerepesi, Laura A ^a,f   Bocker Edmonston, Tina ^b,g   Kucherlapati, Melanie H ^c   Edelmann, Winfried ^d   Kucherlapati, Raju ^c   Kopelovich, Levy ^e   Fishel, Richard ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g Rosetta Genomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NITRIC OXIDE DONATING ASPIRIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; LIFESPAN; LONG TERM CARE; LOW DRUG DOSE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MODELS, ANIMAL; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LONGEVITY; MALE; MICE; MICE, INBRED C57BL; MICROSATELLITE INSTABILITY; NITRIC OXIDE; SURVIVAL RATE;

EID: 79955837946     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0319     Document Type: Article

References (50)

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;20:252-66. (Pubitemid 34196319)
2. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42. (Pubitemid 38332562)
3. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134:1224-37. (Pubitemid 351451998)
4. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
5. Corpet DE, Taché S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002;43:1-21. (Pubitemid 35387251)
6. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005;41:1911-22. (Pubitemid 41557677)
7. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004;10:324-30. (Pubitemid 38881521)
8. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 2007;23:55-9. (Pubitemid 44875911)
9. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002;303:1273-82. (Pubitemid 35424414)
10. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005;312:978-88. (Pubitemid 40293756)
11. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, et al. NO-donating nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 2004;67:2197-205.
12. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001;61:3285-9. (Pubitemid 32695014)
13. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, et al. Cyclo-oxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998;62:367-73.
14. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 2006;66:4503-11.
15. (Min/+)) mice. Biochem Biophys Res Commun 2004;313:784-8.
16. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther 2005;312:989-97.
17. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev 2006;106:302-23.
18. Fishel R, Acharya S, Berardini M, Bocker T, Charbonneau N, Cranston A, et al. Signaling mismatch repair: the mechanics of an adenosine-nucleotide molecular switch. Cold Spring Harbor Symp Quant Biol 2000;65:217-24. (Pubitemid 32611942)
19. Peltomaki P. Lynch syndrome genes. Fam Cancer 2005;4:227-32. (Pubitemid 41242191)
20. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57. (Pubitemid 28521189)
21. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
22. Rüschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstädter F, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A 1998;95:11301-6. (Pubitemid 28450123)
23. McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res 2007;67:10966-75. (Pubitemid 350145926)
24. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rouslek A, et al. An Msh2 conditional knockout mouse model for colorectal cancer and anticancer drug testing. Gasteroenterol 2010;138:993-1002.
25. Kabbarah O, Mallon MA, Pfeifer JD, Edelmann W, Kucherlapati R, Goodfellow PJ. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinog 2003;38:155-9. (Pubitemid 37523707)
26. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
27. Luciani MG, Campregher C, Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007;28:2207-17. (Pubitemid 47543383)
28. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
29. -/- mice. Cancer Res 2001;61:7060-4.
30. Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009;136:780-98.
31. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:365-75. (Pubitemid 351650597)
32. Kohonen-Corish MR, Daniel JJ, te Riele H, Buffinton GD, Dahlstrom JE. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res 2002;62:2092-7.
33. Carini M, Aldini G, Orioli M, Maffei Facino R. In vitro metabolism of a nitro-derivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J Pharm Biomed Anal 2002;29:1061-71.
34. Carini M, Aldini G, Orioli M, Piccoli A, Rossoni G, Maffei Facino R. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci 2004;74:3291-305. (Pubitemid 38501629)
35. Dunlap T, Chandrasena RE, Wang Z, Sinha V, Wang Z, Thatcher GR. Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem Res Toxicol 2007;20:1903-12.
36. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007;50:2424-31. (Pubitemid 46799254)
37. Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun 2007;358:1096-101. (Pubitemid 46829001)
38. Wang P, Song Y, Zhang L, He H, Zhou X. Quinone methide derivatives: important intermediates to DNA alkylating and DNA cross-linking actions. Curr Med Chem 2005;12:2893-913. (Pubitemid 41601563)
39. Rigas B, Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 2008;98:1157-60. (Pubitemid 351481667)
40. Hail N Jr, Cortes M, Drake EN, Spallholz JE. Cancer chemoprevention: a radical perspective. Free Radic Biol Med 2008;45:97-110.
41. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A 2005;102:17207-12. (Pubitemid 41692708)
42. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008;68:8269-77.
43. Tanaka T, Kurose A, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation, ATM activation and apoptosis preferentially in S-phase cells: involvement of reactive oxygen species. Cell Cycle 2006;5:1669-74.
44. Tesei A, Rosetti M, Ulivi P, Fabbri F, Medri L, Vannini I, et al. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med 2007;5:52. DOI:10.1186/1479-5876-5-52.
45. Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 2008;19:199-204.
46. Schmidt-Supprian M, Rajewsky K. Vagaries of conditional gene targeting. Nat Immun 2007;8:665-8. (Pubitemid 46965339)
47. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009;30:183-96.
48. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010;107:1565-70.
49. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
50. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72.